Atlas.
Sign inStart free trial
EDITNASDAQ · US

Editas Medicine, Inc.

Technology · Biological Products, (No Diagnostic Substances)

TechnologyBiological Products, (No Diagnostic Substances)
CEO
Gilmore O'Neill, M.B, M.M.Sc.
Founded
—
IPO Date
—
HQ
Cambridge, MA, United States
Exchange
NASDAQ
Employees
n.a.

Share Price Performance

$3.28 ▲ 60.0%
Last (1 Jul 2026) · $3
Period High · $3.57
Period Low · $1.67
52W: $1.67 – $4.15

Key Metrics

Share Price
$3.28
+1.2% today
Market Cap
$320M
P / E
—
EV / Revenue
5.7x
Revenue Growth
+25.4%
year-on-year
Gross Margin
—
Enterprise Value
$232M
52W High
$4.15
52W Low
$1.67
Avg Volume
2.3M
daily

Sources: SEC filings · Market data as of Jul 6, 2026

Shareholders' Structure
12 known institutional holders·$52M total on record·2026-Q1
BlackRock, Inc.
9.5%·$23M
Renaissance Technologies LLC
4.1%·$10M
Geode Capital Management, LLC
2.4%·$6M
State Street Corp
2.1%·$5M
Jpmorgan Chase & Co
2.0%·$4M
Northern Trust Corp
0.8%·$2M
Goldman Sachs Group Inc
0.6%·$1M
Invesco Ltd.
0.1%·$337,062
Bank Of America Corp
0.1%·$333,119
Point72 Asset Management, L.P.
0.1%·$288,978
Price T Rowe Associates Inc
0.1%·$268
Fmr LLC
0.1%·$263,746
Free Float
78.0%

Sources: SEC filings

Notes: % shown as share of total shares outstanding · Free float = shares outstanding minus all known 13F institutional holdings

What Atlas covers for Editas Medicine, Inc.
OverviewEditas Medicine, Inc. share price history (10 years), key market statistics, and institutional shareholder structure from SEC 13F-HR filings.Business ModelHow Editas Medicine, Inc. generates revenue — product and service segments, geographic breakdown, key operating metrics, and 10-year business evolution sourced from SEC filings.FinancialsEditas Medicine, Inc.'s complete financial history — 10 years of annual revenue, gross margins, operating income, net income, EPS, and free cash flow from SEC filings, plus 12 quarters of quarterly results.Management QualityEditas Medicine, Inc. executive team profiles, insider buying and selling from SEC Form 4, earnings call transcripts, and a track record of guidance delivery vs actual results.Risk FactorsEditas Medicine, Inc.'s annual risk disclosures from SEC filings — full text, 5-year evolution showing how risks have shifted, and year-on-year delta highlighting new and removed risks.NewsAI-synthesised news digest for Editas Medicine, Inc., updated regularly with key developments, earnings updates, product announcements, and material company events.SentimentInvestor sentiment for Editas Medicine, Inc. aggregated from X.com, Reddit, and Hacker News — discussion themes, Bull and Bear signals, and community analysis.Valuation & PeersEditas Medicine, Inc. valuation multiples — P/E, EV/Revenue, EV/EBITDA — compared against a curated set of industry peers using live data from SEC filings. Custom peer selection available.DCF BuilderBuild a discounted cash flow model for Editas Medicine, Inc. with 10 years of pre-filled revenue, margins, and cash flow data from SEC filings. Adjust growth rates, WACC, and terminal assumptions.Atlas AnalysisAtlas AI research synthesis for Editas Medicine, Inc. — business model, financial health, management quality, risk profile, and institutional ownership, grounded exclusively in SEC filings.

Unlock the full analysis

9-tab institutional research sourced directly from SEC filings. No tips, no scores — the same process professional investors use.

7-day free trial · Plus & Pro · No charge during trial